High dose shigella vaccine preparation
AssigneeEveliqure Biotechnologies GmbH
InventorsEszter Nagy, Tamás Henics, Petra Girardi, Irene Neuhauser, Shushan Harutyunyan, Gábor Nagy, Valeria Szijarto
Life of this patent
Estimating the term…
Abstract
A Shigella vaccine preparation comprising 10E8-10E12 CFU of a live, genetically attenuated Shigella flexneri strain that comprises a chromosomal deletion of setBA and which is non-invasive as determined by the Sereny test and an in vitro invasion assay using HeLa cells, wherein the strain comprises an endogenous invasion plasmid that is genetically engineered to incorporate a heterologous expression construct expressing a pathogen-specific antigen.
Claims11
A Shigella vaccine comprising 108-1012 CFU of a live, genetically attenuated Shigella flexneri strain which is of the genotype Shigella flexneri 2457TΔrfbFΔipaBCΔinfAΔsetBA::infA-3x(LTB-ST(N12S)).
A method of treating a subject to induce an immune response against an infection by Shigella and against enterotoxigenic Escherichia coli, by oral administration of a vaccine of 108-1012 CFU of a live, genetically attenuated Shigella flexneri strain which is of the genotype Shigella flexneri 2457TΔrfbFΔipaBCΔinfAΔsetBA::infA-3x(LTB-ST (N12S)).
Dependencies are inferred from the claim text.